Boryung Biopharma
Stories
-
Boryung Biopharma registers Phase 3 trial of BRC-201 in influenza
The study plans to enroll 348 participants and is expected to start in November 2026, with primary completion projected for April 2027. It is a multicenter, randomized, double-blind Phase 3 trial evaluating the efficacy and safety of BRC-201 in adult and adolescent patients with acute uncomplicated influenza.